Recruiting
Phase 2

AV078

Sponsor:

Aeovian Pharmaceuticals, Inc.

Code:

NCT07680322

Conditions

Tuberous Sclerosis Complex

Epilepsy

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

AV078

Placebo

Study Details

Brief summary:

This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to receive AV078 or placebo.

The study will include a Screening Period collecting 4 weeks of pre-treatment Baseline data on seizure frequency, and progress to a 12-week Treatment Period, followed by an in person final follow-up visit approximately 2 weeks after the last dose.

Conditions

Tuberous Sclerosis Complex

Epilepsy

Study ID

NCT07680322

Start date

Oct 5, 2026

Status verified date

Oct, 2026

Completion date

Dec 21, 2027

Anticipated

Primary completion date

Sep 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Participants aged 12 years and above.
  • Diagnosis of TSC based on International TSC Consensus Group criteria.
  • History of failure to adequately control seizures despite having been treated by two or more regimens of anti-seizure medications (ASMs).
  • Receiving a stable dose of ASMs for at least 4 weeks at the start of the Screening Period and for the duration of the study.

Key Exclusion Criteria:

  • History of any infection requiring use of antibiotics within the last four weeks.
  • Current or history of any clinically significant mental or physical illness or condition other than TSC that the Investigator believes would create significant risk for participation in the study.
  • Recent epilepsy surgery/major surgery or planned surgery during the study.
  • Treatment with medicines which act in a similar way.
  • Treatment with medicines that suppress the immune system.
  • Treatment with medicines that may significantly affect the way the body handles the study drug.

Study Design

Enrollment

42 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: AV078

Participants will receive oral AV078 once daily in addition to their stable background anti-seizure medication regimen for 12 weeks. Dosing will be titrated based on measured drug concentrations to achieve target exposure levels.

placebo comparator: Placebo

Participants will receive matching oral placebo once daily in addition to their stable background anti-seizure medication regimen for 12 weeks. Dose adjustments may be performed in a manner similar to active treatment to maintain blinding.

Interventions

AV078

AV078 is a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1) administered orally once daily. Dosing may be adjusted based on measured drug concentrations to achieve target exposure levels.

Placebo

Matching oral placebo administered once daily. The placebo is formulated to match AV078 and may undergo dose adjustments similar to active treatment to maintain blinding.

Primary outcome measure

  • Change From Baseline in Seizure Frequency [ Time Frame: Baseline (28-day period prior to treatment) to end of treatment (Week 12) ]
  • Clinical Global Impression of Change (CGI-C) [ Time Frame: Week 12 ]

Central Contacts and Locations

Central contacts

Davis Ryman, MD, PhD

510-961-1148info@aeovian.com

Locations

London Health Sciences Centre

Recruiting

London, Ontario, Canada, N6A 5A5

Contacts

Principal Investigator:

Andrew House, MD

More Information

Sponsor

Aeovian Pharmaceuticals, Inc.

Last update posted

Nov 20, 2026

Last verified

Oct, 2026

Keywords

  • Tuberous Sclerosis Complex (TSC)
  • Refractory Epilepsy
  • Drug-Resistant Epilepsy
  • Seizures
  • mTORC1 Inhibitor
  • AV078
  • mTOR Pathway

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Aeovian Pharmaceuticals, Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.